Lenmeldy (atidarsagene autotemcel) - MEDICAID - SOUTH CAROLINA

Lenmeldy (atidarsagene autotemcel) — an autologous hematopoietic stem cell–based gene therapy — is covered for treatment of children with early‑onset metachromatic leukodystrophy (PSLI, PSEJ, ESEJ) who have a confirmed pathogenic ARSA mutation and biochemical evidence (low ARSA activity or increased urinary sulfatides), are candidates for allogeneic HSC transplantation but lack an available matched donor, and have not had a prior allogeneic transplant with residual donor cells. Coverage is limited to a single lifetime dose and excludes pregnant or breastfeeding individuals, those with significant active infections or severe hepatic/renal impairment, and is primarily focused on pediatric early‑onset disease rather than adult‑onset phenotypes.

"Adult onset (16 years of age or older) phenotype presenting with dementia"

Sign up to see full coverage criteria, indications, and limitations.